Catherine Delbaldo

11.6k total citations · 2 hit papers
48 papers, 8.3k citations indexed

About

Catherine Delbaldo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Catherine Delbaldo has authored 48 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Catherine Delbaldo's work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Treatment and Pharmacology (9 papers). Catherine Delbaldo is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Treatment and Pharmacology (9 papers). Catherine Delbaldo collaborates with scholars based in France, United States and Switzerland. Catherine Delbaldo's co-authors include Antoine Adenis, Faiza Khemissa-Akouz, Françoise Desseigne, Y. Bécouarn, Rosine Guimbaud, Jean‐Luc Raoul, S. Gourgou-Bourgade, Jaafar Bennouna, Eric Assénat and Olivier Bouché and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Catherine Delbaldo

48 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

2011 5.5k citations Marc Ychou, Catherine Delbaldo et al. profile →
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

2005 934 citations Sandrine Faivre, Catherine Delbaldo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Catherine Delbaldo

Since Specialization

Citations

This map shows the geographic impact of Catherine Delbaldo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Delbaldo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Delbaldo more than expected).

Fields of papers citing papers by Catherine Delbaldo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Delbaldo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Delbaldo. The network helps show where Catherine Delbaldo may publish in the future.

Co-authorship network of co-authors of Catherine Delbaldo

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Delbaldo. A scholar is included among the top collaborators of Catherine Delbaldo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Delbaldo. Catherine Delbaldo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bénéfices médicoéconomiques des formes sous-cutanées de trastuzumab et de rituximab en hospitalisation de jour (étude SCuBA) 2018 ·Bulletin du Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Isabelle Bonnet, (unknown), (unknown), (unknown), Catherine Delbaldo	5
2	Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial 2018 ·Gynecologic Oncology ·(unknown), Florence Joly, Isabelle Ray‐Coquard, Claude El Kouri, (unknown), Dominique Berton-Rigaud, Elsa Kalbacher, Oana Cojocarasu, Michel Fabbro, Jacques Cretin, Alain Zannetti, Sophie Abadie‐Lacourtoisie, (unknown), Anne‐Claire Hardy‐Bessard, Magali Provansal, Emmanuel Blot, Catherine Delbaldo, Anne Lesoin, Gilles Freyer, Benoît You	3
3	Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial 2015 ·Annals of Oncology ·Catherine Delbaldo, Marc Ychou, Ayman Zawadi, Jean‐Yves Douillard, Thierry André, Véronique Guerin‐Meyer, P. Rougier, Olivier Dupuis, Roger Faroux, (unknown), Emmanuel Quinaux, Marc Buyse, Pascal Piedbois	9
4	Dose intensity and toxicity associated with Taxotere formulation 2015 ·Anti-Cancer Drugs ·(unknown), Catherine Delbaldo, (unknown), (unknown), Isabelle Cojean-Zelek, (unknown)	9
5	A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000) 2013 ·European Journal of Cancer ·Catherine Delbaldo, D. Serin, M Mousseau, (unknown), B. Audhuy, Franck Priou, Jean François Berdah, É. Teissier, (unknown), Laurent Zelek, Emmanuel Quinaux, Marc Buyse, Pascal Piedbois	7
6	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease 2012 ·Cochrane Database of Systematic Reviews ·Catherine Delbaldo, Stefan Michiels, Estelle Rolland, Nathalie Syz, Jean‐Charles Soria, Thierry Le Chevalier, Jean‐Pierre Pignon	26
7	Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors 2011 ·Targeted Oncology ·Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie‐Paule Sablin, Maria Serova, Éric Raymond, Sandrine Faivre	33
8	Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development 2010 ·Expert Opinion on Drug Metabolism & Toxicology ·Marie‐Paule Sablin, Chantal Dreyer, (unknown), Mohamed Bouattour, Catherine Delbaldo, Sandrine Faivre, Éric Raymond	10
9	Chemotherapy Has Also an Effect on Primary Tumor in Colon Carcinoma 2008 ·Annals of Surgical Oncology ·Mehdi Karoui, (unknown), Catherine Delbaldo, Antoine Charachon, Alexis Laurent, Pascal Piedbois, Daniel Cherqui, Jeanne Tran Van Nhieu	26
10	Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer 2008 ·British Journal of Cancer ·Iradj Sobhani, Emmanuel Tiret, Rachida Lebtahi, Thomas Aparicio, Emmanuel Itti, Françoise Montravers, (unknown), P. Rougier, Thierry André, J.M. Gornet, Daniel Cherqui, Catherine Delbaldo, Yves Panís, Jean‐Noël Talbot, M. Meignan, Dominique Le Guludec	85
11	Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies 2008 ·European Journal of Cancer ·Sandrine Faivre, Catherine Delbaldo, Valérie Boige, Patricia Pautier, Jean‐Charles Soria, (unknown), Ronald Peck, Marvin B. Cohen, Éric Raymond	7
12	Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults 2008 ·Clinical Cancer Research ·Aurélie Pétain, (unknown), (unknown), Étienne Chatelut, Catherine Delbaldo, Birgit Geoerger, Michel Barrois, Sophie Séronie-Vivien, A. Lecesne, Gilles Vassal	118
13	Population pharmacokinetics of imatinib in children and adults 2008 ·Journal of Clinical Oncology ·Étienne Chatelut, Aurélie Pétain, (unknown), (unknown), Catherine Delbaldo, Birgit Geoerger, Michel Barrois, Sophie Séronie-Vivien, A. Lecesne, Gilles Vassal	2
14	Pharmacocinétique (PK) et pharmacodynamie (PD) de l’imatinib (Glivec®) 2007 ·Therapies ·Catherine Delbaldo	4
15	Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer breakdown → 2005 ·Journal of Clinical Oncology ·Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, (unknown), Nathalie Lassau, Carlo L. Bello, Samuel E. DePrimo, Nicoletta Brega, Giorgio Massimini, Jean‐Pierre Armand, P. Scigalla, Éric Raymond	934
16	Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma 2005 ·European Journal of Cancer ·Catherine Delbaldo, Jean‐Yves Pierga, Véronique Dièras, Sandrine Faivre, Valérie Laurence, Jean-Claude Vedovato, M. Bonnay, M. Mueser, Arno Nolting, Andreas Kovar, Éric Raymond	71
17	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer 2004 ·JAMA ·Catherine Delbaldo, Stefan Michiels, Nathalie Syz, Jean‐Charles Soria, Thierry Le Chevalier, Jean‐Pierre Pignon	254
18	Les inhibiteurs des récepteurs de l’Epidermal Growth Factor (EGF) 2003 ·La Revue de Médecine Interne ·Catherine Delbaldo, Sandrine Faivre, Éric Raymond	5
19	Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagen 2002 ·Journal of the American Academy of Dermatology ·Catherine Delbaldo, Mei Chen, (unknown), Christa Prins, Jules Desmeules, Jean‐Hilaire Saurat, David T. Woodley, Luca Borradori	11
20	Plasminogen activation in melanocytic neoplasia. 1994 ·PubMed ·Catherine Delbaldo, Isabelle Masouyé, Jean‐Hilaire Saurat, Jean‐Dominique Vassalli, André‐Pascal Sappino	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact